Jun 04, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
May 29, 2020
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 26, 2020
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
May 13, 2020
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
May 08, 2020
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Apr 17, 2020
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
Apr 02, 2020
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Mar 24, 2020
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
Mar 05, 2020
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Jan 27, 2020
Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma
Jan 22, 2020
Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
Jan 13, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Jan 09, 2020
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
Dec 04, 2017
Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit
Sep 19, 2017
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference
Sep 18, 2017
Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
Sep 14, 2017
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study
Aug 01, 2017
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
Jun 27, 2017
Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego